Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Apelin

Peptide · Agonist of apelin receptor (APLNR)

Phase 2 Most advanced trial
1 Registered trials

What is Apelin?

Apelin is an endogenous peptide that activates the apelin receptor, a G-protein coupled receptor. It inhibits insulin secretion, decreases glucose levels, and increases insulin sensitivity. The drug is studied in cardiovascular disease and type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Targets
apelin receptor (APLNR)
Mechanism
Agonist of apelin receptor (APLNR)
Pathways
insulin secretion, glucose metabolism, insulin sensitivity
Therapy area
Cardiovascular, Endocrine
In trials of
AZN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
7P5ZL6T59Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03449251 Phase 2 Cardiovascular Diseases Active not recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cardiovascular DiseasesType 2 Diabetes Mellitus

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.